Author

J. Molkentine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

A. Hefner· 2 shared B. Beadle· 2 shared C. R. Pickering· 2 shared D. Molkentine· 2 shared H. D. Skinner· 2 shared J. N. Myers· 2 shared L. Yang· 2 shared M. Abdelhakiem· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Hefner

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.

P. M. Pifer, L. Yang, M. Kumar, T. Xie, M. Frederick, A. Hefner, B. Beadle, D. Molkentine, J. Molkentine, A. Dhawan, M. Abdelhakiem, A. A. Osman, J. N. Myers, C. R. Pickering, V. C. Sandulache, , H. D. Skinner

This study identifies FAK as a driver of therapy resistance in HPV-negative HNSCC, showing its role is dependent on mutant TP53.

bioRxiv · Jun 3, 2022Cancer Biology

Feasibility of Administering Human Pancreatic Cancer Chemotherapy in a Spontaneous Pancreatic Cancer Mouse Model

A. M. Delahoussaye, J. A. Jaoude, T. N. Fujimoto, J. Molkentine, C. J. G. Garcia, J. P. Gay, N. Feng, J. Marszalek, C. M. Taniguchi

This study demonstrates the feasibility of administering clinical chemotherapy regimens, mFOLFIRINOX and gemcitabine/nab-paclitaxel, in a spontaneous pancreatic cancer mouse model, showing improved survival compared to controls.

bioRxiv · Sep 8, 2021Cancer Biology

Inhibition of histone acetyltranserase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a novel gain of function.

M. Kumar, D. Molkentine, J. Molkentine, K. Bridges, T. Xie, L. Yang, A. Hefner, M. Gao, M. J. Frederick, S. Seth, M. Abdelhakiem, B. Beadle, F. M. Johnson, J. Wang, L. Shen, , H. D. Skinner

The paper identifies CREBBP/EP300 as radiosensitization targets in mutant tumors by inhibiting histone acetyltransferase, which represses homologous recombination and increases radiation sensitivity.

bioRxiv · Apr 10, 2020 · PreprintCancer Biology